Display options
Cite
Engelen T, Winkel BM, Rietbergen DD, et al. The next evolution in radioguided surgery: breast cancer related sentinel node localization using a freehandSPECT-mobile gamma camera combination. Am J Nucl Med Mol Imaging. 2015;5(3):233-45
Engelen, T., Winkel, B. M., Rietbergen, D. D., KleinJan, G. H., Vidal-Sicart, S., Olmos, R. A., van den Berg, N. S., & van Leeuwen, F. W. (2015). The next evolution in radioguided surgery: breast cancer related sentinel node localization using a freehandSPECT-mobile gamma camera combination. American journal of nuclear medicine and molecular imaging, 5(3), 233-45.
Engelen, Thijs, et al. "The next evolution in radioguided surgery: breast cancer related sentinel node localization using a freehandSPECT-mobile gamma camera combination." American journal of nuclear medicine and molecular imaging vol. 5,3 (2015): 233-45.
Engelen T, Winkel BM, Rietbergen DD, KleinJan GH, Vidal-Sicart S, Olmos RA, van den Berg NS, van Leeuwen FW. The next evolution in radioguided surgery: breast cancer related sentinel node localization using a freehandSPECT-mobile gamma camera combination. Am J Nucl Med Mol Imaging. 2015 Feb 15;5(3):233-45. eCollection 2015. PMID: 26069857; PMCID: PMC4446392.
Copy Download .nbib Format: NLM
Share it on

Am J Nucl Med Mol Imaging. 2015 Feb 15;5(3):233-45. eCollection 2015.

The next evolution in radioguided surgery: breast cancer related sentinel node localization using a freehandSPECT-mobile gamma camera combination.

American journal of nuclear medicine and molecular imaging

Thijs Engelen, Beatrice Mf Winkel, Daphne Dd Rietbergen, Gijs H KleinJan, Sergi Vidal-Sicart, Renato A Valdés Olmos, Nynke S van den Berg, Fijs Wb van Leeuwen

Affiliations

  1. Interventional Molecular Imaging Laboratory and Nuclear Medicine section, Department of Radiology, Leiden University Medical Center Albinusdreef 2, PO Box 9600, 2300 RC, Leiden, The Netherlands ; Department of Head and Neck Surgery and Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.
  2. Interventional Molecular Imaging Laboratory and Nuclear Medicine section, Department of Radiology, Leiden University Medical Center Albinusdreef 2, PO Box 9600, 2300 RC, Leiden, The Netherlands.
  3. Interventional Molecular Imaging Laboratory and Nuclear Medicine section, Department of Radiology, Leiden University Medical Center Albinusdreef 2, PO Box 9600, 2300 RC, Leiden, The Netherlands ; Department of Nuclear Medicine, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.
  4. Department of Nuclear Medicine, Hospital Clinic-Barcelona Villarroel 170. 08036 Barcelona, Spain.
  5. Interventional Molecular Imaging Laboratory and Nuclear Medicine section, Department of Radiology, Leiden University Medical Center Albinusdreef 2, PO Box 9600, 2300 RC, Leiden, The Netherlands ; Department of Urology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.
  6. Interventional Molecular Imaging Laboratory and Nuclear Medicine section, Department of Radiology, Leiden University Medical Center Albinusdreef 2, PO Box 9600, 2300 RC, Leiden, The Netherlands ; Department of Head and Neck Surgery and Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands ; Department of Urology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.

PMID: 26069857 PMCID: PMC4446392

Abstract

Accurate pre- and intraoperative identification of the sentinel node (SN) forms the basis of the SN biopsy procedure. Gamma tracing technologies such as a gamma probe (GP), a 2D mobile gamma camera (MGC) or 3D freehandSPECT (FHS) can be used to provide the surgeon with radioguidance to the SN(s). We reasoned that integrated use of these technologies results in the generation of a "hybrid" modality that combines the best that the individual radioguidance technologies have to offer. The sensitivity and resolvability of both 2D-MGC and 3D-FHS-MGC were studied in a phantom setup (at various source-detector depths and using varying injection site-to-SN distances), and in ten breast cancer patients scheduled for SN biopsy. Acquired 3D-FHS-MGC images were overlaid with the position of the phantom/patient. This augmented-reality overview image was then used for navigation to the hotspot/SN in virtual-reality using the GP. Obtained results were compared to conventional gamma camera lymphoscintigrams. Resolution of 3D-FHS-MGC allowed identification of the SNs at a minimum injection site (100 MBq)-to-node (1 MBq; 1%) distance of 20 mm, up to a source-detector depth of 36 mm in 2D-MGC and up to 24 mm in 3D-FHS-MGC. A clinically relevant dose of approximately 1 MBq was clearly detectable up to a depth of 60 mm in 2D-MGC and 48 mm in 3D-FHS-MGC. In all ten patients at least one SN was visualized on the lymphoscintigrams with a total of 12 SNs visualized. 3D-FHS-MGC identified 11 of 12 SNs and allowed navigation to all these visualized SNs; in one patient with two axillary SNs located closely to each other (11 mm), 3D-FHS-MGC was not able to distinguish the two SNs. In conclusion, high sensitivity detection of SNs at an injection site-to-node distance of 20 mm-and-up was possible using 3D-FHS-MGC. In patients, 3D-FHS-MGC showed highly reproducible images as compared to the conventional lymphoscintigrams.

Keywords: Sentinel node; breast cancer; freehandSPECT; mobile gamma camera; navigation; nuclear medicine; radioguided surgery

References

  1. Q J Nucl Med Mol Imaging. 2014 Jun;58(2):207-15 - PubMed
  2. Ann Surg Oncol. 2001 Jul;8(6):538-41 - PubMed
  3. Surgeon. 2015 Apr;13(2):69-72 - PubMed
  4. Breast Care (Basel). 2012 Dec;7(6):484-6 - PubMed
  5. Eur J Surg Oncol. 2013 May;39(5):409-16 - PubMed
  6. Eur J Nucl Med Mol Imaging. 2013 Oct;40(11):1656-61 - PubMed
  7. Eur J Nucl Med Mol Imaging. 2012 Jul;39(7):1128-36 - PubMed
  8. J Nucl Med. 2011 Apr;52(4):551-4 - PubMed
  9. Eur Urol. 2007 Jul;52(1):126-32 - PubMed
  10. Arch Surg. 1992 Apr;127(4):392-9 - PubMed
  11. Q J Nucl Med Mol Imaging. 2014 Jun;58(2):140-60 - PubMed
  12. J Biomech. 2005 Nov;38(11):2317-20 - PubMed
  13. J Urol. 2014 Dec;192(6):1810-6 - PubMed
  14. Cancer Biother Radiopharm. 2004 Dec;19(6):784-90 - PubMed
  15. Clin Otolaryngol. 2012 Feb;37(1):89-90 - PubMed
  16. Eur J Nucl Med Mol Imaging. 2009 Jul;36(7):1029-36 - PubMed
  17. Cancer. 2006 Jan 1;106(1):4-16 - PubMed
  18. J Surg Oncol. 2004 Mar;85(3):112-22 - PubMed
  19. Eur J Nucl Med Mol Imaging. 2014 Dec;41(12 ):2257-64 - PubMed
  20. Phys Med. 2015 Feb;31(1):92-7 - PubMed
  21. Phys Med Biol. 2012 May 21;57(10 ):3123-36 - PubMed
  22. Phys Med. 2014 May;30(3):340-5 - PubMed
  23. Cancer Biother Radiopharm. 2008 Feb;23 (1):43-52 - PubMed

Publication Types